Skip to main content

Table 7 Dose and infection-type dependent risk of infection in patients treated with Atogepant vs. Placebo

From: Increased infection risk in patients on preventive CGRP-targeting therapies– a meta-analysis and clinical effect assessment

Atogepant dose

Statistics

Infection

Any

Viral

Bacterial

COVID-19

Urinary

Any

p- value

0.839

0.627

0.285

0.585

0.349

RR

1.02

0.94

1.33

0.85

1.28

Clinical

p-value

0.866

0.655

0.278

0.585

0.344

RR

1.03

0.95

1.33

0.85

1.29

High

p- value

0.866

0.597

0.259

0.585

0.303

RR

1.02

0.93

1.39

0.85

1.35

  1. COVID-19 - Coronavirus disease 2019; UTI– urinary tract infection; RR– risk ratio
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us